61
DAFTAR PUSTAKA
1. Sinniah B, Devi SS, Prashant BS. Epidemiology of Psoriasis in Malaysia: A Hospital Based Study. Med J Malaysia. 2010;65(2):112
2. Traub M, Marshall K. Psoriasis-Pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007;12(4):319-30 3. Gudjonsson J, Elder JT. Psoriasis: epidemiology. Clin Dermatol.
2012;18:377
4. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev. Dermatol. 2006;1(1):63-75
5. Ortonne JP. Recent developments in the understanding of the patogenesis of psoriasis. Br J Dermatol. 1999;54: 1-7
6. Bos JD, De Rie MA. The patogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999; 20: 40-6
7. Suomela S. Studies on the molecular patogenesis of psoriasis. Helsinki University Biomedical Dissertations. 2004; 52:1-81
8. Flisiak I, Przemysław Z, Magdalena R. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. 2010. Cytokine.2013;61: 690
9. Neufeld G, Cohen T,Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal. 1999; 14:1-17
10.Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986; 14(5 Pt 1):863-6
11.Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005; 352: 1899–912 12.Darouti ME, Hay RA. Psoriasis: Highlights on patogenesis, adjuvant
therapy and treatment of resistant and problematic cases (part I). J Egypt Women Dermatol Soc. 2010; 7: 64–70
13.Nograles KE, Brasington RD, Bowcock AM. New insights into the patogenesis and genetiks of psoriatik arthritis. Nat Clin Pract Rheumatol. 2009;5(2):83-91
14.Lowes MA, Bowcock AM, Krueger JG. Patogenesis and therapy of psoriasis. Nature. 2007; 445: 866-73
15.Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis patogenesis. Int J Exp Pathol. 2009; 90(3): 232–48
16.Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005; 64(Suppl 2): ii18–23. 17.Eedy DJ, Griffiths CE, Chalmers RJ. The assessment and management of
psoriasis. NICE Clinical Guidelines 2012;153:34-5
62
18. Smith, A.V. Barker, A.D. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis. British Journal of Dermatology. 2009;161: 987–1019
19.Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64:65-8
20.Nofal A, Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol. 2009 Jul;23(7):803-6.
21.Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner N, Petersen LJ, Kristensen JK. Elevated plasma levels of vascular endothelial growth factor and plasminogen activatorinhibitor-1 decrease during improvement of psoriasis. Inflamm Res. 2002;51(11):563-7.
22.Puxeddu I, Ribatti D, Crivellato E, Schaffer FL. Mast cells and eosinophils: A novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol. 2005;116:531-6
23.Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/ VEGF receptor system and its role under physiological and pathological conditions.Clinical Science. 2005; 109: 227–41
24.Dvorak FH. Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy. J Clin Oncol.2002; 20:4368-80.
25.Olsson AK, Dimberg A, Kreuger J, Welsh LC. VEGF receptor signaling-in control of vascular function. Molecular Cell Biology. 2006; 7: 359-69. 26.Weidemann AK,Crawshaw AA, Young HS. Vascular endothelial growth
factor inhibitors: investigational therapies for the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2013; 6: 233–44.
27.Schonthaler HB, Huggenberger R, Wculek SK, Detmar W, Wagner EF. Systemic anti-VEGF treatment strongly induces reduces skin inflammation in a mouse model of psoriasis. PNAS. 2005; 106(50): 21264-9
28.Zablotna M, Sobjanek M, Nedoszytko B, Lange M, Kozicka D, Glen J, Roszkiewicz. Association of psoriasis with VEGF gene polymorphism in the northern Polish population. J Eur Acad Dermatol Venerol. 2011; 134(1):71-80
29.Cimmino MA. Epidemiology of psoriasis and psoriasis arthritis. Reumatismo. 2007;59(1):19-24
30.Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009; 89:262–6
63
31.Lin TY, et al. Quality of Life in Patients with Psoriasis in Northern Taiwan. Chang Gung Med J. 2011;34:186-96
32.Lin TF. Modifiable health risk factors and medical expenditures – the case of Taiwan. Soc Sci Med. 2008; 67: 1727–36.
33.Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol. 1984;10:965-8.
34.Subagio, Thaha MA, Rusmawardiana, Tjekyan RM. Hubungan Profil Lipid dengan Keparahan Psoriasis di RSUP DR. Mohammad Hoesin Palembang [disertasi]. Palembang: Universitas Sriwijaya; 2011.
35.Setyorini M, Triestianawati W, Wiryadi BE, Alam Jacoeb TN. Proporsi Sindrom Metabolik pada Penderita Psoriasis Vulgaris Berdasarkan Kriteria National Cholesterol Education Program Adult Treatment Panel III di RS DR. Cipto Mangunkusumo dan Sebuah Klinis Swasta Di Jakarta. MDVI. 2012; 39(1):2-9
36.Budiastuti A, Sugianto R. Hubungan Umur dan Lama Sakit Terhadap Derajat Keparahan Penderita Psoriasis. M Med Ind. 2009; 43: 312-6
37.Fatani MI, Abdulghani MM, Al-Afif KA: Psoriasis in the eastern Saudi
Arabia. Saudi Med J. 2002; 23: 213-7
38.Chen HH, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatolo Sinica. 2003; 21: 216–24
39.Brandrup F, Green A: The prevalence of psoriasis in Denmark. Acta Derm
Venereol. 1981; 61: 344-6
40.Hellgren L. Psoriasis. The Prevalence in Sex, Age and Occupational Groups in Total Populations in Sweden. Skin and Rheumatic Diseases. 1967; 256
41.Cooperative Psoriasis Study Group Distribution of psoriasis in China: A nationwide screening in 1984. Chinese Journal of Dermatology. 1986; 19:253–62
42.Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis and Rheumatism. 2009; 61(10):1373-8 43.Artana IP, Gautama A, Adiguna MS, Karmila D. Psoriasis Inversa dan
Kandidiasis Kutis Intertriginosa pada Bayi [disertasi]. Denpasar, Bali: 2011.
44.Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004; 9:136–9
45.Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR. Psoriasis in Norway as observed in a population based Norwegian twin panel. Br J Dermatol. 2005; 153;346-51
64
46.Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom. A population based Study. Arch Dermatol.2005; 141:1537-41
47.Parisi S, Symmons D, Griffiths C, Ashcroft DM. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence.Journal of investigative dermatology. 2013; 133: 377-85
48.Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis. Expert Rev. Dermatol. 2006;1(1):63-75
49.Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009; 89:262–6
50.Diallo M. Psoriasis Epidemiology. J Clinic Case Reports. 2012; 2: 8 51.Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H.
Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp. Dermatol. 2010; 35: 645–9
52.Shimauchi T, Hirakawa S, Suzuki T, Yasuma A, Majima Y, Tatsuno K et al. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. Journal of Dermatology. 2013; 40: 805–12
53.Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010 24 (Suppl 2):10-16.
54.Al-Shobaili H. Serum vascular endothelial growth factor, transforming growth factor-b1 and nitric oxide levels in patients with psoriasis vulgaris: Their correlation to disease severity. J Clin Exp Dermatol Res. 2014, 5:2 55.Martin G, Guerard S, Fortin MM et al. Pathological crosstalk in vitro
between T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. Laboratory investigation. 2012; 92: 1058-70
